Bosutinib-13C, d3
Bosutinib-13C, d3 (SKI-606-13C, d3) is 13C labeled Bosutinib. Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively[1].
Product Specifications
Product Name Alternative
SKI-606-13C, d3
UNSPSC
12352005
Target
Autophagy; Bcr-Abl; Isotope-Labeled Compounds; Src
Related Pathways
Autophagy; Others; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
N#CC1=CN=C2C=C(C(OC)=CC2=C1NC3=CC(O[13C]([2H])([2H])[2H])=C(C=C3Cl)Cl)OCCCN4CCN(CC4)C
Molecular Formula
C25 13CH26D3Cl2N5O3
Molecular Weight
534.46
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Jorge E Cortes, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30 (28) :3486-92.|[3]Miriam Puttini, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66 (23) :11314-22.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
EKC2426 1 Kit, Containing two 96 Well Plates and all necessary reagents
HER2 (Phospho-Tyr1221/Tyr1222) Colorimetric Cell-Based ELISA Kit
Sign In for Pricing
View Details 
